Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

NCT05377307 · clinicaltrials.gov ↗

RECRUITING

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma
Large B-cell Lymphoma
Primary Mediastinal Large B Cell Lymphoma
Follicular Lymphoma Grade 3A
Follicular Lymphoma Grade 3B

Interventions

GENETIC: Pell's lentiviral-based gene-edited immune cell therapy

Sponsor

Pell Bio-Med Technology Co., Ltd.